TScan Therapeutics (TCRX) to Release Earnings on Monday

Key Points

• TScan Therapeutics (NASDAQ:TCRX) is set to announce its Q2 2025 earnings on August 11, with analysts expecting a loss of ($0.28) per share and revenues of $1.31 million.
• In the previous quarter, TScan reported a loss of ($0.26) per share, exceeding analyst expectations, and its stock is currently priced at $1.66 with a market cap of $93.94 million.
• Analysts' ratings vary, with several firms issuing buy ratings and a consensus price target of $7.80, while major shareholder Lynx1 Capital recently increased its stake, owning over 6.7 million shares.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) will likely be announcing its Q2 2025 earnings results before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $1.31 million for the quarter.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.28) by $0.02. TScan Therapeutics had a negative net margin of 2,974.08% and a negative return on equity of 55.76%. The company had revenue of $2.17 million for the quarter, compared to analysts' expectations of $1.62 million. On average, analysts expect TScan Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TScan Therapeutics Stock Up 2.5%

TCRX stock opened at $1.66 on Monday. The company has a current ratio of 8.55, a quick ratio of 8.55 and a debt-to-equity ratio of 0.15. TScan Therapeutics has a twelve month low of $1.02 and a twelve month high of $6.58. The company's 50 day moving average is $1.64 and its two-hundred day moving average is $1.71. The stock has a market cap of $93.94 million, a P/E ratio of -1.52 and a beta of 0.99.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on TCRX shares. Wedbush reaffirmed an "outperform" rating and issued a $7.00 target price on shares of TScan Therapeutics in a report on Tuesday, May 6th. Wall Street Zen raised shares of TScan Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, July 12th. Needham & Company LLC reaffirmed a "buy" rating and issued a $9.00 target price on shares of TScan Therapeutics in a report on Tuesday, April 8th. Finally, HC Wainwright cut their target price on shares of TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $7.80.

Insiders Place Their Bets

In other news, major shareholder Lynx1 Capital Management Lp acquired 1,388,794 shares of the stock in a transaction that occurred on Monday, May 19th. The shares were purchased at an average cost of $1.20 per share, for a total transaction of $1,666,552.80. Following the transaction, the insider directly owned 6,746,141 shares in the company, valued at approximately $8,095,369.20. This represents a 25.92% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. 4.35% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On TScan Therapeutics

A hedge fund recently raised its stake in TScan Therapeutics stock. Goldman Sachs Group Inc. grew its stake in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) by 6.0% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 170,349 shares of the company's stock after purchasing an additional 9,676 shares during the period. Goldman Sachs Group Inc. owned approximately 0.30% of TScan Therapeutics worth $235,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 82.83% of the company's stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.